Larimar Therapeutics (LRMR) Expected to Post Earnings on Thursday

Posted by Geri Gentry on Aug 11th, 2026

Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) will likely be posting its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Larimar Therapeutics to post earnings of ($0.39) per share for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 7:00 AM ET.

Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.08. On average, analysts expect Larimar Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Larimar Therapeutics Stock Down 3.6%

Shares of LRMR opened at $4.01 on Tuesday. The business has a 50-day simple moving average of $3.65 and a two-hundred day simple moving average of $4.00. The stock has a market cap of $416.56 million, a price-to-earnings ratio of -2.06 and a beta of 0.81. Larimar Therapeutics has a 52 week low of $2.71 and a 52 week high of $6.42.

Insider Buying and Selling

In other news, Director Thomas Edward Hamilton acquired 50,000 shares of the business’s stock in a transaction dated Monday, July 6th. The stock was purchased at an average price of $3.34 per share, for a total transaction of $167,000.00. Following the completion of the transaction, the director directly owned 714,798 shares in the company, valued at approximately $2,387,425.32. This trade represents a 7.52% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 4.00% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Larimar Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LRMR. BNP Paribas Financial Markets grew its holdings in Larimar Therapeutics by 75.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 10,146 shares of the company’s stock valued at $33,000 after buying an additional 4,376 shares in the last quarter. Coldstream Capital Management Inc. purchased a new stake in shares of Larimar Therapeutics during the 3rd quarter worth approximately $57,000. Commonwealth Equity Services LLC purchased a new stake in shares of Larimar Therapeutics during the 4th quarter worth approximately $87,000. Price T Rowe Associates Inc. MD boosted its position in shares of Larimar Therapeutics by 26.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 29,008 shares of the company’s stock valued at $111,000 after acquiring an additional 6,038 shares during the last quarter. Finally, Acadian Asset Management LLC bought a new position in shares of Larimar Therapeutics during the 1st quarter valued at approximately $113,000. 91.92% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently weighed in on LRMR shares. Citigroup reaffirmed a “buy” rating on shares of Larimar Therapeutics in a research report on Tuesday, June 30th. Wedbush reduced their target price on shares of Larimar Therapeutics from $12.00 to $11.00 and set an “outperform” rating for the company in a report on Wednesday, August 5th. Robert W. Baird decreased their target price on shares of Larimar Therapeutics from $7.00 to $5.00 and set an “outperform” rating on the stock in a research note on Tuesday, June 30th. Wall Street Zen raised shares of Larimar Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Finally, JPMorgan Chase & Co. assumed coverage on shares of Larimar Therapeutics in a research report on Wednesday, May 27th. They issued an “overweight” rating and a $9.00 price target for the company. Three equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $12.57.

Read Our Latest Stock Analysis on Larimar Therapeutics

About Larimar Therapeutics

(Get Free Report)

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc is based in Bala Cynwyd, Pennsylvania.